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Abstract The objective ofthismulticenter studywas to compare the clinical efficacy, safety, and acceptabilityof Easy-
halers and Turbuhalers for the delivery of budesonide 200 mg/dose twice daily in steroid-na|«ve asthmatic patients.
Three hundred and twenty-six newly diagnosed, steroid-na|«ve adult patients with mild-to-moderate asthma were re-
cruitedintothisrandomized, double-blind, double-dummy, parallel-group study, comprisinga 2-weekrun-inperiod and
8 weeks oftreatment.Patients receivedbudesonide inhalationpowder 400 mg/dayeither via Easyhalers (n= 159) or via
Turbuhalers (n= 167), plus salbutamolinhalationpowder (100 mg/dose) via Easyhalers asrescuetherapy.The studywas
completedby 292 patients:143 inthe Easyhalersgroup and149 intheTurbuhalersgroup.Theprimaryoutcomevariable,
mean morning peak expiratory flow (PEF), improved significantly and almost similarly by 36.3 and 30.6 l/min, respec-
tively, fromrun-in toweeks 728. At weeks 728, themean (SE) difference inmorning PEF between the two treatments
was 7.1 (9.4) l/min (90%CIfrom8.4 to 22.6) onperprotocol analysis, whichwaswithinthe definedlimits for therapeutic
equivalence.There were no significant differences between treatments in terms of secondary efficacy variables or ad-
verse events.However, patients found Easyhalersmore acceptablethanTurbuhalers.Theresults show thatbudesonide
via Easyhalers is clinicallyas effective as PulmicortsTurbuhalerswhenequaldailydosesof budesonide are deliveredto
steroid-na|«ve asthmatic patients.Moreover, patients found Easyhalersmore acceptable thanTurbuhalers, and amajor-
itywouldprefer Easyhalers if given a choice.r2002 Publishedby Elsevier Science Ltd
doi:10.1053/rmed.2002.1311, available online at http://www.idealibrary.comon
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Current national and international guidelines for the
treatment of patients with asthma recommend the early
use of regular anti-in£ammatory therapy with inhaled
corticosteroids.These agents have potent local activity:
they decrease the accumulation and activation of in£am-
matory cells in the asthmatic lung (1), inhibit the release
of in£ammatory mediators from e¡ector cells (2), and
upregulate beta2-receptor function (3). As a result, they
decrease microvascular permeability and mucus forma-
tion (4,5).Received 9 October 2001, accepted is revised form1February 2002.
Correspondence should be addressed to: A.Malinen,Orion
Corporation,ORIONPHARMA, P.O.Box1780, FIN-70701Kuopio,
Finland.Fax: +358-10-4286-444;
E-mail: antti.malinen@orionpharma.com.Clinical studies have provided extensive evidence that,
irrespective of preparation, inhaled corticosteroids have
minimal systemic e¡ects at doses up to 400mg/day in
children and up to 800mg/day in adults (6). The most
common adverse drug reactions of inhaled corticoster-
oids are dysphonia and oral candidiasis (7). Budesonide
is a non-halogenated glucocorticosteroid derivative and
iswidely documented in the treatmentof bronchial asth-
ma (8).
It is generally acknowledged that the inhaler is a key
element in determining the e¡ectiveness of asthma ther-
apy (9).The earliest form of inhaler was the pressurized
metereddose inhaler (PMDI), which remainswidely used
in asthma management (10). However, many patients
have di⁄culty using this device correctly (11) because of
di⁄culty in co-ordinating drug release and inspiration
(12). In addition, pMDIs contain lubricants that may irri-
tate the bronchial membrane, resulting in paradoxical
600 RESPIRATORYMEDICINEbronchoconstriction (13). Furthermore, the most com-
monly used propellant (chloro£uorocarbon (CFC)) has
been implicated in damage to the ozone layer, hence
CFC-containing MDIs will be banned in the near future.
In order to overcome these problems, breath-actu-
ated powder inhalers were developed. One of the ¢rst
multidose powder inhalers to become available wasTur-
buhalers (AstraZeneca, Sweden), which is documented
for the delivery of budesonide in asthma patients as Pul-
micorts Turbuhalers (14^17). The environmental pro-
blems caused by CFC gases in pMDIs are circumvented
by replacing those with alternative propellant, hydro-
£uoroalkane (HFA).
Easyhalers is a new-generation, breath-actuatedmul-
tidosepowder inhaler developedbyOrion Pharma. It has
been shown to be safe and e¡ective for the delivery of
salbutamol (18) and BDP (beclomethasone dipropionate)
(19).Moreover, a meta-analysis of Easyhalers studies has
demonstrated that patients prefer Easyhalers to pMDI
and Turbuhalers (20). Additional advantages of Easyha-
lers include a dose counter, high dosing accuracy, insen-
sitivity of ¢ne particle dose to inspiratory £ow rate, and
ease of use (20).
Easyhalers and Turbuhalers havebeen shown to deli-
ver an equivalent ¢ne particle dose in vitro (21), with a
comparable in vivo lung deposition of Tc-labeled budeso-
nide (22).Thepresent study was undertaken to compare
the clinical e⁄cacy, safety, patient acceptability and tol-
erability of Easyhalers and Turbuhalers for the delivery
of budesonide 200mg/dose twice daily in steroid-na|«ve
asthmatic patients.
MATERIALSANDMETHODS
Patients
Adult asthmatic out-patients who had been diagnosed
with bronchial asthma no more than 2 years previously
were recruited into the study from 30 centers in Ger-
many. Inclusion criteria were: age18^70 years; non-smo-
kers for at least 6 months prior to entry (maximum
smokinghistoryof onepack per day for 5 years); a forced
expiratory volume in1s (FEV1) 60^90% of the predicted
valuemeasuredwithin 4weeksbefore or during the ¢rst
visit; additionally, at least one of the following criteria 4
weeks before study entry or during the ¢rst visit:
(a) At least 15% increase in FEV1 or PEF after a
sympathomimetic inhalation (200^400mg
salbutamol, 500^1000mg terbutaline or 200mg
fenoterol).
(b) At least 15% decrease in FEV1 after an exercise
tolerance test.
(c) At least 20% diurnal variability in PEF on at
least 4 days during 1 week, based on the followingformula (23):
Diurnal variaability ¼ Highest PEF2Lowest PEF
Highest PEF
 100:
Exclusion criteria were: hypersensitivity to budeso-
nide or lactose; any exacerbation of asthma or a respira-
tory infection during the preceding 4 weeks;
hospitalization due to asthma during the previous 12
months; treatmentwith inhaled or systemic corticoster-
oids, sodium cromoglycate or nedocromil within 12
weeks before the ¢rst visit or for more than 30 days
per yearduring theprevious 5 years;manifestheart con-
dition (NYHA Class II^IV); severe hepatic or renal dis-
ease; inadequately controlled hyperthyroidism; chronic
bronchitis; diabetes mellitus (type I or II); any clinically
signi¢cant deviation in safety laboratory parameters.
Women were excluded if they were pregnant or breast-
feeding or, if fertile, without reliable contraception. All
patientswho hadparticipated in this or anyother clinical
trial within 8 weeks prior to study entry were also ex-
cluded.
Study design and treatments
This study was carried out according to a randomized,
double-blind, double-dummy, parallel-group design.
After a 2-week run-in period during which all patients
used salbutamol Easyhalers (Buventol Easyhalers
100mg/dose,Orion Pharma, Finland) as needed, patients
were randomized to receive 200mg of budesonide either
via Easyhaler (Gionas Easyhalers 200mg/dose, Orion
Pharma, Finland) or viaTurbuhalers (PulmicortsTurbu-
halers 200mg/dose, AstraZeneca, Sweden) twice daily
(at 0600^0800 and 1900^2100 hours) for 8 weeks
(Fig.1).Thosepatients randomized to receivebudesonide
via Easyhalers concurrently inhaledplacebo (lactose) via
Turbuhalers and vice versa.The appearance and weight
of placebo was indistinguishable from the active treat-
ment.Patientswere instructed torinse theirmouthwith
water and spit it out after inhalation of each drug. The
patients were trained to use both inhalers properly ac-
cording tomanufacturer’s instructions.The inhaler tech-
nique was also checked during the control visits, which
took place at 2-week (visits1^4) and 4-week (visit 5) in-
tervals.
Salbutamol Easyhalers could be used as rescuemedi-
cation during the treatment period but preferably not
during the 6h prior to home PEF measurements or fol-
low-up visits to the clinic for spirometry. Patients were
also permitted to take a1-week course of an oral corti-
costeroid if needed, but any further use resulted inwith-
drawal from the study.
All study documents were reviewed and approved by
the Ethics Committee of the LandesPrztekammer Bran-
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FIG. 1. Flowchartofthe study (n= plannedgroup size).
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written informed consent and the study was conducted
according to the principles of the current revision of the
Declaration of Helsinki (24).
Outcome variables
The primary e⁄cacy variable was morning PEF mea-
sured at home. Daily morning (0600^0800 hours) and
evening (1900^2200 hours) PEFwasmeasuredby the pa-
tient at home using a standard Vitalograph Peak Flow
Meter (Vitalograph,Cat.No. 43.000G, Hamburg).Three
successive exhalations were recorded and the best value
was used for the ¢nal analysis.Mean PEF valueswere cal-
culated for the run-in period and for treatmentweeks1^
2, 3^4 and 7^8. Secondary e⁄cacy variables consisted
of evening PEF measured at home; FEV1 and FVC mea-
sured at follow-up visits; number of salbutamol inhala-
tions per day during the treatment period; severity
scores for asthma symptoms during the day and night;
visual analog scale (VAS) scores for e⁄cacy, as deter-
mined by the patients and the investigators; and diurnal
PEF variability.
The intensity of asthma symptoms (dyspnea, wheeze
and cough) was scored daily by the patients and entered
onto their diary cards, where 0 = no symptoms,1 =mild
symptoms, 2 = moderate symptoms and 3 = severe
symptoms. Patients were asked to specify whether the
symptoms occurred during the day or night or early
morning.
Both patients and investigators evaluated the e⁄cacy
of the treatment with a 100mmVAS, ranging from ‘not
e⁄cient’ (0mm) to ‘very e⁄cient’ (100mm). These eva-
luations were performed after the run-in period and
after 8 weeks of treatment.Patients were asked to record the occurrence of
any adverse event into the diary. In addition, the investi-
gator inquired on each visit whether patient had
had any untoward medical events since last visit.
The investigators performed a visual examination for or-
opharyngeal candidiasis at each follow-up visit. Morning
(0700^0900 hours) serum cortisol measurements were
performed before and after the treatment period to
evaluate the possible e¡ect of budesonide on the
HPA axis.
Patient acceptability of the devices was determined
after 4 weeks of treatmentusing a questionnaire consist-
ing of 10 questions, and aVAS, ranging from ‘very poor’
(0mm) to ‘very good’ (100mm).
Statistical analysis
The overall hypothesis tested in the study was therapeu-
tic equivalence of Gionas (budesonide) Easyhalers and
Pulmicorts Turbuhalers.This was de¢ned as a 90% con-
¢dence interval within 730 l/min for estimated treat-
ment di¡erence in mean morning PEF during treatment
weeks 7^8. Additional hypotheses were that improve-
ment in morning PEF could be detected during treat-
ment with Budesonide Easyhalers, and that treatments
with Budesonide Easyhalers and Pulmicorts Turbuha-
lers were equally safe, tolerable and acceptable. A
two-sided P value of o5% was considered statistically
signi¢cant if not otherwise stated.
For the primary e⁄cacy variable (morning PEF mea-
surements), data were analyzed on both an intention-
to-treat (ITT) and a per protocol (PP) basis. Secondary
e⁄cacy variable datawere analyzedonlyon an ITT basis.
Data from all patients entered into the study were ana-
lyzed for safety and acceptability.
TABLE 2. Reasons for studydiscontinuation
Easyhalers
group
Turbuhalers
group
Adverse event 1 3
E⁄cacy F 1
Loss to follow-up 10 4
Protocolviolation 1 1
Withdrawal of consent 2 9
Other 2 F
TABLE 1. Demographic and baseline patient information.Values aremeans (SD) except for sex, number of atopics, number of
patientswith FEV1o80% of predicted, andnumberof patients demonstrating the inclusion criteria (a)^(c)
Parameter Easyhalers
n = 159
Turbuhalers
n = 167
Age (years) 41 (14) 43 (13)
Female/male 102/57 101/66
Height (cm) 170 (9) 167 (9)
Weight (kg) 73 (15) 76 (17)
Duration of asthma symptoms (years) 0.4 (0.7) 0.5 (0.7)
Numberof atopics 46 54
Morning PEF (l/min) 356 (103) 358 (110)
Evening PEF (l/min) 366 (104) 367 (112)
FEV1
a
Liters 2.47 (0.64) 2.45 (0.67)
%Ofpredicted 76.6 (12.8) 76.7 (13.0)
o80%Ofpredicted 97 109
FVCa
liters 3.00 (0.82) 2.99 (0.80)
% Ofpredicted 78.5 (14.9) 79.0 (14.5)
(a) At least15% increase in FEV1or PEFafter a
sympathomimetic inhalation
98 110
(b) At least15% decrease in FEV1
after exercise-tolerance test
24 20
(c) At least 20% diurnalvariability 18 22
At leasttwo ofthe criteria above (a^c) 17 15
None of criteria above (a^c) due to a screening failure ormissingdata 2 F
aBaseline FEV1and FVCvalues are frommeasurements performed at visit1, atthe beginning ofthe run-inperiod.
602 RESPIRATORYMEDICINETherapeutic equivalencewas analyzedusing analysis of
covariance (ANCOVA). Improvement in the Easyhalers
group was analyzed using analysis of variance (ANOVA).
Spirometry values were analyzed with a repeated mea-
surements ANCOVAmodel, while the number of salbu-
tamol inhalations per day, intensity scores for asthma
symptoms,VAS scores for e⁄cacy and diurnal PEF varia-
tion were analyzed as change from run-in to treatment
weeks 5^8. VAS scores for device acceptability were
compared using theWilcoxon signed rank test.
Safety analyses includedmorning serum cortisol using
the ANCOVA model, and adverse events, which were
classi¢ed by System Organ Class and by preferred term
according to the WHO coding system. Oropharyngeal
candidiasis was analyzed descriptively.
RESULTS
Patients
A total of 326 patients were recruited into the study
from30 centers inGermany:159 in the Easyhalers group
and 167 in the Turbuhalers group. Demographic and
baseline features of all patients in each treatment group
are shown in Table 1. There were no statistically signi¢-
cantdi¡erencesbetween the groups for anyof the speci-
¢ed parameters.Two hundred and ninety-two patients completed the
study: 143 in the Easyhalers group and149 in theTurbu-
halers group. Sixteen patients in the Easyhalers group
and 18 patients in the Turbuhalers group discontinued
the study for various reasons (Table 2).
E⁄cacy
According to both the PP and ITTanalyses, meanmorn-
ing PEF improved signi¢cantly from baseline (run-in) to
weeks 7^8 with both preparations, with a mean (SD) in-
crease of 36.3 (6.6) l/min in the Easyhalers group and
30.6 (5.7) l/min in theTurbuhalers group on PP analysis
(Fig. 2, Table 3). At weeks 7^8, the mean (SE) di¡erence
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FIG. 2. Meanmorning PEF values (per protocol analysis) with
standard errorofmean.
TABLE 3. Mean (SE ) improvementinmorning PEF values
(l/min) fromrun-intoweeks 7^8
Mean (SE)
improvement
90% CI P value
Easyhalers
Perprotocol 36.3 (6.6) 23.3^49.3 o0.0001
Intention-to-treat 34.3 (6.2) 21.9^46.6 o0.0001
Turbuhalers
Per protocol 30.6 (5.7) 19.4^41.9 o0.0001
Intention-to-treat 28.5 (5.4) 17.7^39.2 o0.0001
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(9.4) l/min (90% CI from 8.4 to 22.6) on PP analysis and
7.0 (9.0) l/min (90% CI from 7.9 to 21.9) on ITTanalysis,
which was within the de¢ned limits for therapeutic
equivalence.The e¡ectof sympathomimetic use on treat-
mentdi¡erencewas analyzed separatelybyexcluding the
patients who had used the rescue medication regularly.
The result of this analysis did not di¡er from the original
result.
Evening PEF values improved in accordance
with morning PEF values, with a mean (SE) improvement
from baseline to weeks 7^8 of 32.2 (5.7) l/min in the
Easyhalers group and 27.9 (5.3) l/min in theTurbuhalers
group.
Spirometric indices also improved to a similar extent
in both treatment groups over the study period (TableTABLE 4. Mean (SD) changes in spirometry (FEV1and FVC) value
Easyhalers
End of run-in Week 8 End
FEV1 2.62 (0.70) 2.80 (0.76) 2.5
FVC 3.09 (0.88) 3.28 (0.93) 3.104). Between the end of run-in and the ¢nal visit at week
8, the mean (SD) improvement in FEV1 was 0.2 (0.5) l in
the Easyhalers group and 0.2 (0.5) l in theTurbuhalers
group. Similarly, the mean (SD) improvement in FVCwas
0.2 (0.6) and 0.3 (0.7) L for the Easyhalers andTurbuha-
lers groups, respectively. The corresponding change in
mean FEV1 as percent predicted was 5.1 (15.6) % points
in the Easyhalers group and 7.5 (15.5) in the Turbuha-
lers group (treatment di¡erence 0.06 with a 95% CI
from0.22 to 0.09).The change inmean FVC as percent
predictedwas 4.8 (16.4)%points in the Easyhalers group
and 7.2 (18.3) in theTurbuhalers group (treatment di¡er-
ence1.21with a 95% CI from4.85 to 2.43).
Use of rescue medication decreased during the study
in both treatment groups. In the Easyhalers group, the
mean (SD) number of salbutamol inhalations per day de-
creased from1.8 (2.2) during the run-in period to 0.7 (1.3)
during treatment weeks 5^8 (Po0.001). In theTurbuha-
lers group, the corresponding ¢gures were1.5 (2.2) and
0.6 (1.0) (Po0.001), respectively.
The incidence of asthma symptoms was higher during
the run-in period than during the treatment period and
was similar in both treatment groups (between
treatments, weeks 5^8: day symptoms P=0.83, night
symptoms P=0.74) (Table 5). Mean night-time symptom
scores were lower than mean day-time symptom scores
in both groups. There were also no statistically signi¢-
cant di¡erencesbetween the treatments in terms of e⁄-
cacy based on VAS scores by investigator (P=0.61) or
patient (P=0.58), which improved during the course of
the study in both groups.Mean (SD) VAS e⁄cacy scores,
as assessedbypatient, increasedby 24.4 (28.0)mm in the
Easyhalers group and by 21.7 (28.3)mm in theTurbuha-
lers group, giving mean (SD) VAS e⁄cacy scores at the
end of treatment of 78.2 (16.7) and 77.5 (17.0)mm in each
group, respectively.
Diurnal variability in PEF values decreased to a similar
extent in both treatmentgroups.Thus, mean (SD) diurnal
variability in PEF changed from 7.3 (4.4)% duringrun-in to
5.2 (4.3)% during weeks 7^8 in the Easyhalers group,
and from 7.4 (5.0) to 5.5 (4.4)% in theTurbuhalers group.
Acceptability
Themean (SD) VAS score for device acceptability was sig-
ni¢cantly higher for Easyhalers than for Turbuhalerss (l) fromthe end of run-in toweek 8.
Turbuhalers Treatmentdi¡erence
(95% CI)
of run-in Week 8
9 (0.79) 2.83 (0.84) 0.07 (^0.16^0.02)
(1.01) 3.36 (1.14) 0.07 (^0.190.05)
TABLE 5. Meanday- andnight-time symptom scores (% oftheoreticalmaximum) duringrun-in and treatmentweeks 5^8
Easyhalers Turbuhalers
Dyspnea Wheezing Cough Dyspnea Wheezing Cough
Day
Run-in 22.3 12.1 29.6 20.8 15.2 32.5
Weeks 5^8 11.1 5.1 16.6 13.1 7.8 17.5
Night
Run-in 12.2 8.3 20.2 14.2 10.0 22.1
Weeks 5^8 4.8 2.8 9.6 7.7 4.2 9.8
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604 RESPIRATORYMEDICINE(74.8 [18.4]mm vs 56.3 [23.6]mm, respectively;
Po0.0001). Easyhalers also scored higher thanTurbuha-
lers for most questions in the device acceptability
questionnaire (Fig. 3). In particular, patients using
Easyhalers found it easier to know when the drug
had been received, and howmuch drug remained in the
device. Furthermore, 63.8% patients said they would
have chosen Easyhalers compared with 12.4% who
preferred Turbuhalers and 22.8% who expressed no
preference.
Safety
Adverse events that were considered possibly or
probably related to study treatment occurred in 3.1% of
Easyhalers patients duringboth the ¢rst and the second
half of the treatment period. In the Turbuhalers
group, 4.8% of patients experienced such events during
the ¢rst half of treatment and 2.4% during the
second half of treatment. Overall, 12 adverse drug
reactions (ADRs) were reported in the Easyhalers
group and 16 in the Turbuhalers group. Most of
these were mild or moderate in nature. Dysphonia
(3 and 4 events, respectively) and pharyngitis (4 and 5events, respectively) were the most common reported
ADRs.
Four patients withdrew from the study as a result of
adverse events: one in the Easyhalers group (irritation
of the oralmucosa and throat) and three in theTurbuha-
lers group (bacterial bronchitis; dyspnea and cough; and
deterioration of asthma).
Only two SAEs occurred during the study, neither of
whichwas considered related to study treatment.These
consisted of one neoplasm (cervical carcinoma) in the
Easyhalers group and one respiratory system disorder
(hospitalization because of dyspnoea and urinary tract
infection) in theTurbuhalers group.
In the Easyhalers group mean (SD) morning
serum cortisol value was 424 (219)nmol/l after
run-in, and slightly higher at visit 8 (443 [191] nmol/l).
In the Turbuhalers group, the trend was similar
(from 368 [187] to 419 [194] nmol/l). At the end of
treatment, only seven patients had serum cortisol
values below the reference range (138^690nmol/l) (25):
one in the Easyhalers group and six in theTurbuhalers
group. The number of oral, 1-week steroid courses was
three in the Easyhalers group and one in theTurbuha-
lers group.
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The results of this study demonstrated that Gionas (bu-
desonide) Easyhalers is as e¡ective as PulmicortsTur-
buhalers when equal daily doses of budesonide are
delivered to steroid-na|«ve asthmatic patients. This was
evident frommeasurements of pulmonary function; diur-
nal PEF variability; asthma symptom scores; number of
salbutamol inhalations per day; and VAS scores for e⁄-
cacy.
The design of this study was carefully considered to
ensure the optimal conditions for a rigorous comparison
of the e⁄cacy of two budesonide inhalers: Gionas Easy-
halers and Pulmicorts Turbuhalers. Firstly, since in-
haled corticosteroids may take days or weeks to exert
their maximal e¡ect, the recommendedminimum dura-
tion for this type of study is 4 weeks (26). Hence, in the
present study an 8-week treatment periodwas selected
in order to obtain a reliable assessment of the e⁄cacy,
safety and acceptability of the devices under investiga-
tion. In addition, the dosage of budesonide used in this
study (400mg/day) is low compared with the average
starting dose in adults (27,28) and should be in the steep
part of the budesonide dose^response curve (7), thus,
enhancing the reliability of comparison between the
two preparations investigated. The inclusion of a sepa-
rate placebo control groupwas considered to be unethi-
cal in this population of newly diagnosed, untreated
asthmatic patients. Joyce et al. studied the placebo e¡ect
in a meta-analysis of 33 asthma drug therapy trials (29).
According to their observations, a mean absolute de-
crease of 2.24 l/min in PEF was observed among placebo
groups, which supports the rationale for not including a
placebo group in our study.
During the trial, the primary e⁄cacy variable and all
secondary e⁄cacy variables improved clearly during
treatment and to a similar extent in both groups. An im-
provement in PEF of similar magnitude has been re-
ported in previous studies with corticosteroids in
steroid-na|«ve asthmatic patients (15,19).
The safety and tolerability of the two preparations
was good, and was comparable between the two treat-
ment groups. The frequencies of adverse events
(whether considered potentially drug-related or not)
were also similar with both treatments, with no signi¢-
cant e¡ect on the HPA axis. Although morning serum
cortisol is not an ideal method for assessing such an ef-
fect, because of large diurnal variation, a single blood
sample is the only practical method for determination
of serum cortisol in a large, multicenter study of this
type.
Tests to assess the acceptability of the devices re-
vealed a clear preference for Easyhalers by a majority
of patients. In all,10 questions on the questionnaire, Easy-
halers was considered at least as good asTurbuhalers,
and 63.8% of patients said they would prefer Easyhalers,given the choice. Moreover, Easyhalers scored statisti-
cally signi¢cantly better than Turbuhalers on the VAS
test for acceptability.While evaluating the acceptability
results it shouldbenoticed thatpatientshad a somewhat
more thorough experience of the Easyhalers device
than of the Turbuhalers, because salbutamol Easyha-
lers was used as a rescue medication in both groups.
However, the ¢ndings of this study are supported by
the meta-analysis of nine Easyhalers clinical studies,
which showed that the majority of patients (60%) pre-
ferred Easyhalers to Turbuhalers, and found Easyha-
lers easier to use (64%) thanTurbuhalers (20).
The questionnaire also revealed that a majority of pa-
tients found it easier to know when the drug had been
receivedwith Easyhalers (69.3%), comparedwithTurbu-
halers (2.1%).This ¢nding is likely to re£ect an additional
bene¢t of incorporating a small amount (8mg) of lactose
to the budesonide dry powder, which is used to ensure a
high level of dose reproducibility (20).The amount of lac-
tose is su⁄cient for the patient to detect, but below the
level likely to cause a reaction in lactose intolerant pa-
tients (30).
CONCLUSIONS
The results of this study indicate that Gionas (budeso-
nide) Easyhalers is as e¡ective as PulmicortsTurbuha-
lers when equal daily doses of budesonide are delivered
to steroid-na|«ve asthmatic patients. The mean improve-
ment in morning the primary e⁄cacy variable (PEF)
seen in both treatment groups was statistically signi¢-
cant.There were no signi¢cant di¡erences between the
treatment groups in terms of any of the secondary e⁄-
cacy variables. Similarly, there were no clinically signi¢-
cant di¡erences in terms of adverse events between the
studygroups, and theseweremostlymild ormoderate in
nature. Neither treatment suppressed the HPA axis, as
determined bymorning serum cortisol values. BothVAS
testing and the use of a questionnaire demonstratedbet-
ter patient acceptability of Easyhalers compared with
Turbuhalers. In addition, the majority of patients said
that they would choose Easyhalers.
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